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1  |  INTRODUC TION
The limited replicative capacity of cultured human cells, resulting in 
senescence, was first described by Hayflick and Moorhead (1961) 
and has since been implicated to play an important role during in vivo 
ageing and age- related diseases (van Deursen, 2014). Senescence, a 
stable proliferative arrest, occurs in response to diverse damaging 
stimuli triggering up- regulation of cyclin- dependent kinase inhib-
itors (CDKIs), altered gene expression and subsequent nuclear 
and cellular morphological changes (Sharpless & Sherr, 2015). Two 
families of CDKIs, including p16INK4A (p16) and p21Cip1/Waf1 (p21), can 
independently initiate senescence programmes by directly binding 
and inhibiting cyclin- CDK complex phosphorylation of retinoblas-
toma (RB) (Dyson, 1998).
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Abstract
Senescence, a state of stable growth arrest, plays an important role in ageing and 
age- related diseases in vivo. Although the INK4/ARF locus is known to be essential 
for senescence programmes, the key regulators driving p16 and ARF transcription re-
main largely underexplored. Using siRNA screening for modulators of the p16/pRB 
and ARF/p53/p21 pathways in deeply senescent human mammary epithelial cells (DS 
HMECs) and fibroblasts (DS HMFs), we identified EGR2 as a novel regulator of senes-
cence. EGR2 expression is up- regulated during senescence, and its ablation by siRNA 
in DS HMECs and HMFs transiently reverses the senescent phenotype. We demon-
strate that EGR2 activates the ARF and p16 promoters and directly binds to both the 
ARF and p16 promoters. Loss of EGR2 down- regulates p16 levels and increases the 
pool	of	p16−	p21−	‘reversed’	cells	in	the	population.	Moreover,	EGR2	overexpression	
is sufficient to induce senescence. Our data suggest that EGR2 is a direct transcrip-
tional activator of the p16/pRB and ARF/p53/p21 pathways in senescence and a novel 
marker of senescence.
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Study of p16 regulation has revealed numerous pathways that 
converge to regulate p16 and by extension the INK4/ARF locus, which 
also encodes p15INK4B and p14ARF/p19ARF (ARF) Gil & Peters, 2006; 
Martin et al., 2014). Importantly, ARF functions to inhibit MDM2 
ubiquitination and degradation of p53, leading to up- regulation of 
p21, a transcriptional target of p53. Thus, the INK4/ARF locus forms 
a pivotal link between the two key senescence initiation cascades 
(Zhang et al., 1998).
Epigenetic repression of the INK4/ARF locus is controlled by two 
polycomb repressive complexes (PRC1 and PRC2; Gil et al., 2004). 
In addition, individual transcription factors directly repress the 
p16 promoter, including the hedgehog pathway component, GLI2 
(Bishop et al., 2010), and homeobox proteins, such as HLX1, which 
act to recruit the PRC2 complex to the locus (Martin et al., 2013). 
Similarly, T- box proteins, TBX2 and TBX3, directly repress the ARF 
promoter (Brummelkamp et al., 2002; Jacobs et al., 2000).
Although it is well established that ETS1 mediates p16 induc-
tion in fibroblasts by the RAS/RAF/MEK cascade during oncogenic 
signalling, leading to oncogene- induced senescence (Serrano et al., 
1997), the upstream pathways activating the INK4/ARF locus in ep-
ithelial and fibroblast senescence are not well understood. To date, 
overexpression of the homeobox protein, MEOX2, has been iden-
tified to induce senescence in keratinocytes and fibroblasts by di-
rectly binding to and activating the p16 promoter (Irelan et al., 2009), 
and overexpression of E2F1 induces senescence in fibroblasts via 
increased ARF expression (Dimri et al., 2000). Depending on the 
cellular context, β- catenin can directly activate (Wassermann et al., 
2009) or repress p16 (Delmas et al., 2007), whilst FOXO proteins can 
directly activate p15 and ARF (Katayama et al., 2008) or repress p16 
(Yalcin et al., 2008).
Furthermore, recent evidence has suggested that senescence is 
a multi- step, dynamic process throughout which the senescent phe-
notype evolves (Kim et al., 2013). Deep senescence (DS) takes over 
7– 10 days to develop post- senescence induction. For example, in ep-
ithelial cells, it is defined when cultures at p16- dependent stasis un-
dergo no further expansion upon at least two serial passages (Lowe 
et al., 2015, Methods). In fibroblasts, it is further characterised by 
additional markers of senescence, most notably the senescence- 
associated secretory phenotype (SASP) (Coppé et al., 2008; Rodier 
et al., 2009), accompanied by elevated reactive oxygen species (ROS) 
levels (Lowe et al., 2015; Passos et al., 2010) and a loss of lamin B1 
(Freund et al., 2012). Despite our growing understanding of the elab-
oration of the senescent state, there is a lack of knowledge of the 
key regulatory pathways upstream of the p16/pRB and ARF/p53/
p21 pathways in DS.
We have previously demonstrated that DS is reversible in p16- 
positive primary adult human mammary epithelial cells (HMECs) 
using p16 siRNA transfection (Lowe et al., 2015). Of relevance, 
p16- dependent epithelial senescence is independent of ARF/p53/
p21 pathway activation (Garbe et al., 2009), whereas senescence in 
primary adult human fibroblasts engages both the ARF/p53/p21 and 
p16/pRB pathways (Alcorta et al., 1996; Figure 1a). We took note of 
previous work in human neonatal foreskin fibroblasts (HCA2) which 
demonstrated that p53 knockdown in senescence reinitiates DNA 
synthesis but with limited proliferation (Gire & Wynford- Thomas, 
1998), and subsequent findings that p53 or pRB inactivation in neo-
natal foreskin fibroblasts (BJ), with low levels of p16, reversed se-
nescence (Beauséjour et al., 2003). However, p53 inactivation or p16 
shRNA knockdown followed by p53 inactivation in foetal lung WI38 
fibroblasts, with higher levels of p16, did not reverse senescence, 
leading the authors to suggest that activation of the p16/pRB path-
way may provide a dominant second barrier to senescence reversal 
(Beauséjour et al., 2003).
Here, we show that DS in primary adult human fibroblasts with 
high p16 levels can be reversed using transfection of p16 siRNA 
in combination with p21 siRNA. Subsequently, we perform siRNA 
screens in DS HMECs and human mammary fibroblasts (HMFs) in 
order to further understand the key regulators upstream of the p16/
pRB and ARF/p53/p21 pathways which drive senescence. In this 
study, we present evidence that early growth response 2 (EGR2) 
acts as a transcriptional activator of p16 and ARF in senescence and 
is a novel marker of senescence.
F I G U R E  1 Deep	senescence	(DS)	in	primary	adult	human	mammary	fibroblasts	is	reversible.	(a)	Schematic	illustrating	epithelial	and	
fibroblast senescence and the DS reversal strategy. (b) Early proliferating (EP) fibroblasts at P11 were serially passaged until they reached 
senescence at P29. Deeply senescent (DS) fibroblasts were defined as a population which did not expand when kept in culture for 3 weeks 
post- senescence (P29 + 3). No expansion was observed in DS fibroblasts kept in culture for a further 130 days. N = 1 between P4 and P6; 
N = 2 or more between P7 and P29 + 3; N = 1 P29 + 3 + 130 days. Error bars = SD of at least two independent experiments. (c– j) DS HMFs 
were forward transfected with 30 nM control siRNA (siGLO), 30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21) or 15 nM p16 siRNA together 
with 15 nM p21 siRNA (p16+p21) and fixed 5 days post- transfection (b– e, h– i), harvested for RTqPCR at 72 h post- transfection (f) and 
conditioned medium collected 5 days post- transfection (g). (c) Bar chart showing mean cell number/well. *p < 0.05, **p < 0.01. Error bars, SD 
from four independent experiments, each performed with three replicates. (d) DS HMFs stained with DAPI (blue) and Cell Mask (red). Size 
bar 100 µm. Right panel = digital zoom. Size bar 20 µm. (e) Multi- parameter analysis of cellular and nuclear morphological measures. Colour 
coding used to illustrate the number of Z scores of the experimental siRNA value from the siGLO mean. (f) DS HMFs stained with DAPI 
(blue) and anti- BrdU (green). Size bar 50 µm. Bar chart showing mean BrdU positive nuclei for each condition. *p < 0.05, ***p < 0.001. Error 
bars, SD from three independent experiments, each performed with three replicates. (g) RTqPCR analysis of mRNA levels of IL- 6 in DS HMFs 
***p < 0.001, ****p < 0.0001. Error bars, SD from two independent experiments, each performed with two replicates. (h) Representative 
ELISA of secreted IL- 6 levels in DS HMFs. (i) DS HMFs stained with DAPI (blue) and anti- 8- oxoguanine (green). Size bar 100 µm. Bar chart 
depicting mean 8- oxoguanine positive cells for each condition. *p < 0.05. Error bars, SD from two independent experiments, each performed 
with three replicates. (j) Representative images of DS HMFs stained for senescence- associated beta- galactosidase (SA- β- Gal) activity (blue). 
Size bar 50 µm
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2  |  RESULTS
2.1  |  Reversal of deep senescence in fibroblasts
Current literature suggests that senescence is a dynamic process 
and	that	fibroblasts	in	‘light’	senescence	(with	low	p16	levels)	can	
be reversed, whereas DS fibroblasts (with high p16 levels) have 
entered a distinct, irreversible state (Beauséjour et al., 2003). As 
such, we began by asking whether fibroblast DS (with high p16 
and p21 levels) is truly irreversible. Building on previous work 
in which we have reversed DS in p16- positive DS HMECs (Lowe 
et al., 2015), we hypothesised that transient knockdown using 
previously validated p16 (Bishop et al., 2010) together with p21 
(Borgdorff et al., 2010) siRNAs in DS fibroblasts would induce a 
‘reversed	 phenotype’	 as	 characterised	 by	 a	 panel	 of	 senescence	
markers (Figure 1a).
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To investigate this hypothesis, we employed senescent HMF and 
human dermal fibroblasts (HDFs) that had been serially passaged to se-
nescence and cultured for a further 21 days to ensure a deeply senes-
cent state with high p16 and p21 levels (Figure 1b, Figure S1, Methods) 
and developed an efficient protocol to introduce siRNA into these clas-
sically hard to transfect cells (Methods). Subsequently, we depleted p16 
and/or p21 mRNA in DS HMFs or HDFs with potent siRNAs (Figure 
S2A,B) and assessed the impact on numerous cellular and molecular 
markers classically associated with senescence in comparison to DS 
cells transfected with siGLO (a negative control targeting cyclophilin B 
(PPIB);	‘DS	+	siGLO’).	Whilst	depletion	of	p16 with siRNA in DS HMFs 
(‘DS	+	p16	siRNA’)	did	not	significantly	alter	the	arrested	phenotype	or	
cellular and molecular markers of senescence, p21	depletion	(‘DS	+	p21	
siRNA’)	 significantly	 increased	 cell	 number	 and	modulated	 some	 fea-
tures of senescence morphology towards an early proliferating (EP) 
phenotype, namely, significantly decreased cell area, nuclear area and 
nuclear elongation; and significantly increased nuclear roundness and 
cell elongation (Figure 1c- e). Strikingly, depletion of both p16 and p21 
in	DS	HMFs	and	HDFs	(‘DS	+	p16	+	p21	siRNA’)	stimulated	a	stronger	
reversion to an EP morphology as characterised by multiple cellular and 
molecular markers (Figure 1c– e, Figure S3). Using a panel of established 
senescence markers, we sought to explore further the consequences 
of p16 and p21 knockdown. Quantification of proliferation using 




that observed in EP HMFs (Figure S1D), indicating that a greater pro-
portion	of	the	‘DS	+	p16	+	p21	siRNA’	HMFs	progress	through	S	phase	
during the 16- h BrdU pulse than the EP HMFs. In agreement with the 
reversed	phenotype,	‘DS	+	p16	+	p21	siRNA’	HMFs	also	displayed	down-	
regulation of the SASP proinflammatory signature in comparison to 
‘DS	+	siGLO’	HMFs,	as	illustrated	by	significantly	decreased	expression	
of the cytokine IL- 6 (Figure 1g) and decreased IL- 6 secretion (Figure 1h). 
In line with the literature, IL- 8 expression and secretion were also inves-
tigated but found not to be a feature of the SASP in DS HMFs (data not 
shown; Coppé et al., 2008). We also measured levels of 8- oxoguanine, 
a marker of reactive oxygen species and oxidative damage, and found 
a	significant	decrease	 in	the	 ‘DS	+	p16	+	p21	siRNA’	population	com-
pared	to	‘DS	+	siGLO’	HMFs	(Figure	1i).	Furthermore,	investigation	of	
senescence- associated beta- galactosidase (SA- β- Gal) activity in DS 
HMFs following transfection, suggested a potential decrease in SA- β- 
Gal	activity	in	‘DS	+	p16	+	p21	siRNA’	HMFs	compared	to	‘DS	+	siGLO’	
HMFs (Figure 1j). Together, our data indicate that senescence appears to 
be	transiently	reversed	in	the	‘DS	+	p16	+	p21	siRNA’	HMFs.
2.2  |  siRNA screening reveals novel 
regulators of senescence
We next sought to identify novel genes that regulate the senes-
cent phenotype. Initially, we interrogated our previously published 
gene expression datasets to identify genes whose expression was 
significantly up- regulated in HMEC DS relative to EP HMECs and 
down- regulated following p16 siRNA knockdown (Figure 2a; Lowe 
et al., 2015; GEO: GSE58035, q < 0.05). In order to distinguish be-
tween	 the	 genes	 driving	 senescence	 and	 downstream	 ‘passenger’	
genes, a siRNA screen of the top 190 genes was performed in DS 
HMECs (Table S1). Each gene was targeted by a pool of three siRNAs 
(30 nM Ambion). To determine the effect on a panel of senescence 
markers for each of the 190 siRNAs, the siGLO transfected control 
provided a baseline for Z score generation. Using high- content anal-
ysis, 28 siRNAs (14.7%) were identified to strongly induce reversal 
in the DS HMECs as defined by an increase in cell number and the 
loss of a panel of senescence markers (i.e. mimicking the HMEC phe-
notype generated by p16 siRNA). Accordingly, these 28 genes were 
classified as potential regulators of senescence (Figure 2b).
To further investigate the relationships between these potential 
28 regulators of senescence, we constructed a protein interaction 
map. Briefly, these 28 genes were probed for protein interactors using 
the BioGRID database (Figure S4). Using Panther, KEGG pathways 
and Gene Ontology (GO) bioinformatics tools, 61 genes emerged 
(the 28 previously identified regulators, which includes p16 and 33 
protein interactors) which grouped into six functional categories: im-
mune response; cell adhesion/cytoskeleton; metabolism; transcrip-
tion; growth/proliferation; and protein/vesicle trafficking (Figure S5).
We next asked whether the siRNA hits that emerged from 
the initial HMEC screen could also play a role in senescence in DS 
HMFs using this extended protein interaction network. As DS HMF 
reversal was found to require siRNA knockdown of both p16 and 
p21, we hypothesised that the regulators identified in the DS HMEC 
screen may additionally require knockdown of either the p16/pRB 
or the ARF/p53/p21 pathway to induce reversal in the DS HMFs. 
Accordingly, DS HMFs were screened with 60 target siRNAs (27 
regulators, excluding p16 and 33 interactors) in three conditions: 
30 nM siRNA individually (Group 1); 15 nM siRNA in combination 
with 15 nM p16 siRNA (Group 2); or 15 nM siRNA in combination 
with 15 nM p21 siRNA (Group 3) (Figure 2c).
Using the same approach as described for the DS HMEC siRNA 
screen, a hit list was generated for each of the three conditions 
(Groups 1, 2 and 3) (Figure 2d,e). One siRNA transfected individually 
(Group 1) was defined as a hit, namely early growth response 2 (EGR2), 
a transcription factor involved in several cellular processes including 
cell cycle and proliferation (Parkinson et al., 2004; Srinivasan et al., 
2012). Two siRNAs in combination with p16 siRNA (Group 2), fraser 
extracellular matrix complex subunit 1 (FRAS1) and ring protein 20 
(RNF20), an E3 ubiquitin ligase, were defined as hits (Figure 2d– e). 
Finally, 45 of the 60 siRNAs in combination with p21 siRNA (Group 
3) were defined as hits. Strikingly, eight of these 45 siRNAs induced 
an	increase	in	cell	number	similar	to	the	‘DS	+	p16	+	p21	siRNA’	DS	
HMF control, including EGR2 and S100A4 siRNA. As the 28 regulator 
siRNAs in the screen were identified as hits for senescence reversal 
in p16- dependent DS HMECs, it is perhaps unsurprising that 21 of 
these siRNAs were identified as hits requiring additional knockdown 
of the ARF/p53/p21 pathway to reverse senescence in DS HMFs. 
Furthermore, 24 of the 33 interactors investigated in this screen 
    |  5 of 14TYLER ET aL.
F I G U R E  2 High-	content	screening	for	regulators	of	senescence.	(a)	Schematic	illustrating	mRNA	microarray	data	which	identified	top	190	
genes with increased expression in the deeply senescent (DS, blue) versus the early proliferating (EP, red) and reversed (R, purple) HMECs. 
(b) Results of DS HMEC screen performed twice, in triplicate. Colour coding used to illustrate the number of Z scores of the experimental 
siRNA value from the siGLO mean. Heatmap of Z scores for cell number, cell area, cell elongation and cell roundness following transfection 
of DS HMECs. DS HMECs stained with DAPI (blue) and Cell Mask (red) following transfection with control siRNA (siGLO) or siRNAs targeting 
representative hit (EGR2). Size bar 100 µm. Right panels = digital zoom. Size bar 100 µm. (c) Schematic illustrating the experimental design 
of the siRNA screen. DS HMFs were forward transfected with the 60 target siRNAs in three conditions: 30 nM siRNA individually (Group 
1); 15 nM siRNA in combination with 15 nM p16 siRNA (Group 2); and 15 nM siRNA in combination with 15 nM p21 siRNA (Group 3). (d) DS 
HMFs stained with DAPI (blue) following transfection with control siRNAs (siGLO, p16, p21, p16 + p21) or siRNAs targeting representative 
hits (EGR2, MYL12A, BHLHE41, ACTG1, FN1, DAPL1, JUP). Size bar 100 µm. Right panels = digital zoom. Size bar 20 µm. (e) DS HMF screen 
performed twice, in triplicate. Colour coding used to illustrate the number of Z scores of the experimental siRNA value from the siGLO 
mean. Heatmap of Z scores for cell number following transfection of DS HMFs with Group 1, Group 2 or Group 3 siRNAs. A brief function is 
assigned to each siRNA
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were also identified as Group 3 hits, highlighting the utility of the 
bioinformatics approach.
The top candidates from Group 1 (EGR2) and Group 2 (FRAS1), to-
gether with an additional 12 candidates from Group 3 were selected 
for further investigation (HIF1A, HSP90AA1, S100A4, BHLHE41, 
FN1, ACTG1, PPFIA1, JUP, CD9, PDCD6IP, MYL12A and DAPL1). We 
performed a more detailed, independent screen with these 14 siR-
NAs using multi- parameter analysis of senescence- associated mor-
phological markers with four conditions: 30 nM siRNA individually 
(Group 1), 15 nM siRNA in combination with 15 nM p16 siRNA 
(Group 2); or 15 nM siRNA in combination with 15 nM p21 siRNA 
(Group 3) (Figure S6). In addition, the impact of an increased indi-
vidual siRNA dose (60 nM, Group 1B) was performed to identify the 
most potent reversed phenotype (Figure S6).
Strikingly, 11 of the 14 siRNAs transfected individually signifi-
cantly decreased cell area in a dose- dependent manner (Group 1, 
Group 1B; Figure S7). Of these, six siRNAs transfected individually 
also significantly decreased nuclear area in a dose- dependent man-
ner (Group 1, Group 1B) and EGR2 was the only siRNA transfected 
individually (Group 1, Group 1B) to also significantly increase cell 
elongation in a dose- dependent manner. As such, EGR2 was the 
only siRNA that did not require knockdown of p16 and p21 to sig-
nificantly increase cell number (Figure 2) and significantly alter three 
senescence- associated morphologies towards a reversed phenotype 
in a dose- dependent manner (Figure S7). Taken together, these data 
suggest that EGR2 may be acting upstream of p16 in epithelial DS 
and p16 and p21 in fibroblast DS. To our knowledge, no direct re-
lationship between EGR2 and senescence has previously been de-
scribed, and thus, we sought to explore this finding in more detail.
2.3  |  EGR2 is a novel regulator of senescence
As EGR2 was identified as the top hit for reversal in both the DS 
HMEC and HMF screens, we next wanted to explore the role of EGR2 
in senescence. First, we validated mRNA knockdown for the EGR2 
siRNA pool in DS HMFs (Figure 3a) and subsequently deconvoluted 
the EGR2 siRNA pool (EGR2 1, 2 and 3) to determine the efficacy of 
each individual siRNA targeting EGR2.	 ‘EGR2 1’	siRNA	was	the	least	
potent (Figure S8), which was subsequently reflected in the pheno-
type (Figure 3b– d). Using multi- parameter phenotypic analysis to con-
trol	for	off-	target	effects,	we	identified	‘EGR2 3’	siRNA	as	the	most	
potent siRNA transfected individually (Figure S8) which significantly 
increased cell number and significantly reversed cell area, nuclear 
area	and	cell	elongation	(Figure	3b–	d).	‘EGR2 2’,	the	second	most	po-
tent siRNA transfected individually (Figure S8), produced a modest 
increase in cell number and significantly reversed nuclear area and cell 
elongation	(Figure	3b–	d).	Finally,	the	least	potent	siRNA,	‘EGR2 1’,	only	
significantly reversed cell elongation compared to the DS + siGLO 
control (Figure 3d). Further characterisation of the changes to the 
senescence phenotype following ablation of the EGR2 in DS HMFs 
revealed a significant down- regulation of the SASP factor, IL- 6, at the 
transcript level (Figure 3e) and at the secreted protein level (Figure 3f). 
As mentioned previously, IL- 8 is known not to be a feature of the DS 
HMF SASP (data not shown, Coppé et al., 2008).
It is important to note that the human genome encodes four 
EGR transcription factors, EGR1- 4, that share three highly homol-
ogous DNA binding zinc finger domains that can bind to the same 
GC- rich consensus DNA binding motif (Beckmann & Wilce, 1997). 
In addition, a role for EGR1 has previously been implicated in RAF- 
induced oncogene- induced senescence (OIS) of human BJ fibroblasts 
(Carvalho et al., 2019) and replicative senescence (RS) of murine em-
bryonic fibroblasts (Krones- Herzig et al., 2003). As such, we wanted to 
investigate the expression of EGR family members in HMEC epithelial 
senescence and HMF senescence. EGR2 was the only member of the 
EGR family with significantly increased gene expression in DS com-
pared to EP HMECs, and EGR2 was the only member of the EGR fam-
ily whose gene expression significantly decreased in reversed HMECs 
(GEO: GSE58035). Furthermore, investigation of EGR family member 
expression levels in EP and DS HMFs revealed a significant increase 
in EGR2, but not EGR1, EGR3 or EGR4 expression levels (Figure 3g). 
Collectively, these data suggest that EGR2 might be the key EGR fam-
ily member acting to regulate senescence in HMECs and HMFs.
Subsequently, to further explore whether EGR2 activity and reg-
ulation is conserved across multiple senescence models and occurs 
in vivo in human tissues, we performed data mining of existing GEO 
F I G U R E  3 EGR2	knockdown	in	vitro	reverses	senescence-	associated	morphologies	and	down-	regulates	SASP	component,	IL-	6	and	
EGR2 protein levels increase in deep epithelial and fibroblast senescence in vitro. (a) RTqPCR analysis of mRNA levels of EGR2 in DS HMFs 
following siGLO or EGR2 knockdown. **p < 0.01. Error bars, SD from two independent experiments, each performed with two replicates. (b) 
Representative immunofluorescence images of DS HMFs stained with DAPI (blue), EGR2 (green) and Cell Mask (red) following transfection 
with siGLO or deconvoluted EGR2 siRNAs at 5 days post- transfection. Size bar 50 µm. Right panel = digital zoom. Size bar 30 µm. (c) Bar 
chart depicting median EGR2 nuclear foci following siGLO or EGR2 siRNA knockdown. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars, SD 
from two independent experiments, each performed with three replicates. (d) Representative immunofluorescence images of DS HMFs 
stained with DAPI (blue) and Cell Mask (red) following transfection with control siRNAs (siGLO, p16, p21, p16 + p21) or deconvoluted siRNAs 
targeting EGR2. Size bar 50 µm. Heatmap depicting Z scores for phenotypic validation following EGR2 siRNA pool deconvolution in DS 
HMFs. Two independent experiments were performed, each in triplicate. (e) RTqPCR analysis of mRNA levels of IL- 6 in DS HMFs following 
siGLO or EGR2 knockdown. ***p < 0.001. Error bars = SD from two independent experiments, each performed with two replicates. (f) 
Representative ELISA of secreted IL- 6 levels in DS HMFs following transfection with control siRNA (30 nM siGLO) or 30 nM EGR2 siRNA 
(EGR2). (g) RTqPCR analysis of mRNA levels of EGR family members (EGR1, EGR2, EGR3, EGR4) in EP and DS HMFs. **p < 0.01. Error bars, 
SD from two independent experiments, each performed with two replicates. (h) EP and DS HMECs and HMFs stained with DAPI (blue) and 
EGR2 (green). Size bar 50 µm. (i) Frequency distributions of EGR2 nuclear foci in EP and DS HMECs and HMFs. *p < 0.05. Two independent 
experiments, each containing three technical repeats were performed
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datasets for HDF RS, bleomycin- induced stress- induced premature 
senescence (SIPS) in BJ foreskin fibroblasts and RAS oncogene- 
induced senescence (OIS) in WI38 lung fibroblasts (Martínez- 
Zamudio et al., 2020) in vitro, as well as human skin and whole- blood 
with age in vivo (STAR Methods). The abundance of EGR2 increased 
during senescence across all three senescence models (Figure S9A, 
p < 0.05). Importantly, EGR2 expression increased in vivo in aged 
human skin. In addition, a recent whole- blood gene expression meta- 
analysis looking at over 7000 human samples showed that EGR2 ex-
pression significantly increases with age (Figure S9, p < 0.01, Peters 
et al., 2015). Thus, increased EGR2 expression appears to be a fea-
ture of both in vitro senescence and in vivo ageing signatures.
EGR2 possesses a nuclear localisation signal and functions to 
regulate gene transcription within the nucleus, thus we hypothesised 
that functional EGR2 would be localised within the nucleus during 
senescence. Immunofluorescence staining in EP and DS HMECs 
revealed a significant increase of nuclear EGR2 foci in DS HMECs 
compared to the EP population and in DS HMFs compared to EP 
HMFs (Figure 3h– i). Further investigation of EGR2 levels in a third 
model of senescence, oncogene- induced senescence (OIS) in IMR90 
lung fibroblasts (Figure S9B), identified a significant increase in nu-
clear EGR2 foci in OIS fibroblasts compared to the vector control 
(Figure S9C). These findings support our previous mining of mRNA 
datasets and show that an increase in EGR2 is also observed at the 
protein level with the expected subcellular localisation (Figure 3h– i), 
thus identifying EGR2 as a novel marker of senescence in both DS 
HMECs, HMFs and OIS IMR90 fibroblasts.
Finally, to explore the potential mechanisms through which 
EGR2 may be driving senescence and identify a panel of genes that 
might be regulated by EGR2 during senescence, we asked if genes 
identified to be up- regulated in senescence in the HMEC gene ex-
pression array were enriched for the previously published EGR2 
consensus binding sequences (ACGCCCACGCA; Jolma et al., 2013; 
Mathelier et al., 2016) compared to randomly sampled background 
gene sets (Figure S10A– C). Interestingly, there was a small but sig-
nificant enrichment for EGR2 binding sites at the promoters of genes 
up- regulated in HMEC DS. Furthermore, ten of these genes were 
identified as hits for senescence reversal in the DS HMEC screen, 
including p16, and nine of these were also identified as hits in the 
HMF siRNA screen, including the top hit S100A4, suggesting that 
EGR2 may act as a senescence regulator by activating the expression 
of these genes.
2.4  |  EGR2 regulates senescence via the p16/
pRB and ARF/p53/p21 pathways
Although previous work has identified EGR2 binding to the p21 pro-
moter (Srinivasan et al., 2012; Zheng et al., 2013), no investigation 
has yet been performed on other pathways of senescence (Figure 4j). 
Further examination of the INK4/ARF locus revealed previously un-
reported hypothetical EGR2 binding sites (ACGCCCACGCA; Jolma 
et al., 2013; Mathelier et al., 2016) in the p16, p15 and ARF promoter 
regions, indicating a potential for EGR2 to bind to and regulate ex-
pression of p16, p15 and ARF. As p15 was found not to be expressed 
in DS HMFs (Figure S10D), we explored the potential action of EGR2 
on the p16 and ARF promoters. To this end, we first investigated ac-
tivation of the ARF promoter using transiently co- transfected U2OS 
cells with an expression vector encoding one of each of the four 
members of the EGR family or E2F1, a transcription factor known 
to directly up- regulate ARF which acts as a positive control (Dimri 
et al., 2000), together with pGL3 luciferase reporter constructs har-
bouring either the promoter sequence 800 bp or 3.4 kb upstream of 
the transcriptional start site of ARF (pGL3 ARF 800 or plGL3 ARF 
F I G U R E  4 EGR2	directly	binds	to	ARF and up- regulates p16 and ARF which is sufficient to induce proliferation arrest. (a– b) Mean 
luciferase values for activation of pGL3 luciferase reporter constructs harbouring either the promoter sequence up to 800 bp or 3.4 kb 
upstream of the transcriptional start site of ARF (pGL3 ARF 800 or ARF 3.4, respectively) following co- transfection of U2OS cells with 
expression vectors encoding each of the EGR family members (EGR1- 4) or E2F1 (a positive control). Error bars, SD from two experiments. 
(c) Chromatin immunoprecipitation (ChIP) showing relative levels of EGR2 or E2F1 binding to the ARF promoter in quiescent Kit225 human 
T- lymphocytes or Kit225 lymphocytes following IL- 2 activation. *p < 0.05, **p < 0.01. Error bars = SD from three independent experiments. 
(d) Representative images of Hs68, p16−/− Leiden or p16+/− Q cells following infection with retroviral particles expressing EGR2 cDNA and 
selection on puromycin. Images taken at the same magnification. (e) Hs68 fibroblasts or p16+/− Q cells were infected with retroviral particles 
expressing the indicated cDNAs, selected on puromycin and assessed for proliferative capacity by periodic trypsinisation and cell counting. 
**p < 0.01, ***p < 0.001, ****p < 0.0001. Error bars = SD from three experiments. (f) Mean luciferase values for activation of pGL3 luciferase 
reporter constructs harbouring p16 promoter sequence (pGL3 p16) following co- transfection of U2OS cells with expression vectors 
encoding each of the EGR family members (EGR1- 4) or E2F1 (a positive control). Error bars, SD from six experiments. (g) ChIP showing 
relative levels of EGR2 binding to the p16 promoter in EP and DS HMFs. *p < 0.05. Error bars = SD from four independent experiments. 
(h) Representative Western blots depicting p16 levels in DS HMFs following transfection with control siRNA (siGLO), p16 siRNA (p16), p21 
siRNA (p21), p16 siRNA together with p21 siRNA (p16 + p21) or individual EGR2 siRNA 3 (EGR2 3). Lysates were probed for mouse anti- p16 
(JC8) and the rabbit anti- GAPDH antibody was used as a loading control. (i) Densitometry analysis of p16 levels in transfected DS HMFs. 
Analysis was performed using ImageJ software. Bars denote mean density levels. One- way ANOVA and Dunnett's test **p < 0.01. N = 2 
throughout. Error bars = SD normalised to siGLO siRNA of two independent experiments. (j) Representative immunofluorescence images of 
DS HMFs stained with DAPI (blue), p16 (green) and p21 (red) following transfection with control siRNA (siGLO), p16 siRNA (p16), p21 siRNA 
(p21), p16 siRNA together with p21 siRNA (p16 + p21) or EGR2 siRNA together with p21 siRNA (EGR2 + p21). Digital zoom. Size bar 50 µm. 
(k)	Bar	chart	depicting	mean	p16	and	p21	negative	(p16−	p21−)	nuclei	for	transfected	DS	HMFs.	*p < 0.05, **p < 0.01. Error bars, SD from 
two independent experiments, each performed with three replicates. (l) Schematic summarising the proposed relationship between EGR2 
(dark blue), ARF (purple), p16 (light blue), MDM2, p53 and p21 (red) in senescence.
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3.4, respectively, Figure 4a,b). Cells transfected with the pGL3 ARF 
800 or with the complete ARF promoter, pGL3 ARF 3.4, displayed a 
significant increase in luciferase activity following transfection with 
the EGR2 expression vector or E2F1 positive control, but not EGR1, 
EGR3 or EGR4 expression vectors, thus confirming EGR2 as a direct 
activator of the ARF promoter (Figure 4a,b, Figure S11).
Validation of the interaction between EGR2 and the ARF pro-
moter was performed using chromatin immunoprecipitation (ChIP) 
on cross- linked DNA from quiescent interleukin- 2 (IL- 2)- dependent 
Kit225 human T- lymphocytes, with low levels of ARF expression and 
Kit225 cells following IL- 2 activation which results in increased ARF 
expression (Gutierrez del Arroyo, 2007). Subsequently, ChIP was 
performed with polyclonal antibodies against EGR2 or E2F1, which 
acted as a positive control. Addition of IL- 2 to Kit225 cells resulted 
in significantly increased binding of E2F1 and EGR2 to the ARF pro-
moter, demonstrating that EGR2 can be detected at the endogenous 
ARF promoter (Figure 4c).
In order to further explore the role of EGR2 in senescence, we 
introduced retroviral particles expressing EGR2 cDNA into normal 
human Hs68 diploid fibroblasts. In line with our previous observa-
tions that loss of EGR2 reverses senescence, stable overexpression 
of EGR2 was sufficient to induce proliferation arrest (Figure 4d,e). 
Interestingly, p16−/−	Leiden	cells	and	p16+/−	Q	cells	also	underwent	
proliferation arrest following overexpression of EGR2, indicating 
EGR2- mediated up- regulation of ARF is sufficient to induce senes-
cence in the absence of p16 (Figure 4d,e).
We next explored activation of the p16 promoter and found that 
cells co- transfected with one of each of the four members of the 
EGR2 family or E2F1, together with a pGL3 p16 construct displayed 
a significant increase in luciferase assay activation with the EGR2 
or EGR4 expression vectors or E2F1 positive control, confirming 
EGR2 and EGR4 as direct activators of the p16 promoter (Figure 4f). 
As EGR4 expression is not increased in DS compared to EP HMECs 
or HMFs ((GEO: GSE58035, Figure 3g), we suggest that EGR2 may 
be important for activation of the p16 promoter in epithelial and 
fibroblast senescence. Furthermore, ChIP performed in EP and DS 
HMFs revealed significantly increased binding of EGR2 to the p16 
promoter in DS HMFs, thus confirming that EGR2 can bind to the 
endogenous p16 promoter (Figure 4g).
If EGR2 functions to activate the p16 promoter and up- regulate 
p16 expression, we hypothesised that ablation of EGR2 in senes-
cent cells would lead to a decrease in p16 levels. Subsequent in-
vestigation of DS HMFs transfected with an individual potent 
EGR2	siRNA	(‘DS	+	EGR2	3	siRNA’)	revealed	a	significant	decrease	
in p16 protein levels compared to DS + siGLO HMFs (Figure 4h,i). 
Interestingly, the level of p16 in DS + EGR2 3 siRNA HMFs was sim-
ilar to DS + p16 + p21 siRNA HMFs, indicating a down- regulation 
of p16 in DS + EGR2 3 siRNA HMFs comparable to reversed HMFs 
(Figure 4h,i). Using immunofluorescence staining and high- content 
analysis, we further examined p16 and p21 on a cellular level and 
found a significant increase in the proportion of double negative 
(p16−	p21−)	‘reversed’	cells	in	DS	HMFs	following	EGR2	knockdown	
in combination with p21	siRNA	(‘DS	+	EGR2	+	p21 siRNA) compared 
to the DS + p21 siRNA HMFs, an increase similar to that seen in the 
reversed DS + p16 + p21 HMFs (Figure 4j,k). Taken together, these 
data indicate that EGR2 functions to transcriptionally up- regulate 
p16 and ARF expression in senescence which is sufficient to induce 
proliferation arrest, demonstrating that EGR2 acts as a novel tran-
scriptional activator upstream of p16/pRB and ARF/p53/p21 path-
ways in senescence (Figure 4l).
3  |  DISCUSSION
Here, we show that DS can be transiently reversed in human fibro-
blasts using p16 siRNA in combination with p21 siRNA transfection, 
as characterised by the loss of a panel of senescence markers. It is 
important to note here that we have shown that siRNA mediated 
reversal of DS HMFs is transient, with population growth slowing 
and cells reverting to a senescence morphology by 7 days post- 
transfection. Further investigation is required to assess the effect 
of long- term, stable knockdown on DS cells, including the impact on 
DNA damage and telomeres. However, as previous work in our group 
demonstrated that p16 siRNA knockdown can reverse DS HMECs, 
the discovery that p16 + p21 siRNA knockdown can transiently re-
verse DS HMFs provided a unique opportunity for uncovering novel 
senescence regulators in epithelial and fibroblast DS. Using siRNA 
screening, we identified novel regulators of senescence in HMECs 
and HMFs, including the transcription factor EGR2, extracellular ma-
trix protein FRAS1, E3 ubiquitin ligase RNF20 and calcium- binding 
protein S100A4. Further investigation of the top hit, EGR2, revealed 
that EGR2 ablation enables resumption of the cell cycle, reversed 
senescence- associated morphologies and decreased expression and 
secretion of the SASP component, IL- 6. We demonstrate that EGR2 
accumulates during in vitro senescence in DS HMECs, DS HMFs and 
OIS IMR90 lung fibroblasts. Furthermore, we re- mined existing data-
sets to reveal an increase in EGR2 expression in RS HDFs, SIPS BJ 
fibroblasts, OIS WI38 fibroblasts and in human tissue during in vivo 
ageing. As such, we have identified EGR2 as a novel marker of senes-
cence across multiple senescence models, including p16- dependent 
epithelial	DS,	p16−	and	p21−	dependent	fibroblast	DS,	fibroblast	RS,	
OIS and SIPS. Examination of genes differentially expressed in DS 
HMECs identified EGR2 binding sites in p16 and nine siRNAs found 
to reverse DS HMEC and HMFs, including one top reversal hit in 
the DS HMFs, S100A4. Further investigation of the INK4/ARF locus 
revealed previously unreported EGR2 binding sites in all the p16, p15 
and ARF promoters. In support of this, we demonstrated that EGR2 
activates the p16 and ARF promoters and that EGR2 directly binds to 
both the p16 and ARF promoters. Furthermore, stable EGR2 overex-
pression was sufficient to induce proliferation arrest in the presence 
or absence of p16. Lastly, we observed a decrease in p16 protein 
levels in DS HMFs following EGR2 knockdown and an increase in 
the	p16−	p21−	double	negative	subpopulation	in	DS	HMFs	following	
EGR2 and p21 knockdown.
Mutations in EGR2 have been identified to lead to inherited pe-
ripheral neuropathies, including Charcot- Marie- Tooth Type 1 (Šafka 
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Brožková	 et	 al.,	 2012),	 a	 demyelinating	 form	 associated	with	 dys-
regulated Schwann cell proliferation and cell cycle exit (Atanasoski 
et al., 2006). Accumulating evidence indicates that EGR2, a tran-
scription factor, plays the role of regulator in these processes 
(Decker, 2006; Topilko et al., 1994; Zorick et al., 1996) and has been 
shown to directly bind to the p21 promoter in myelinating rat sci-
atic nerve (Srinivasan et al., 2012). In addition, a role for EGR2 as a 
tumour suppressor has been implicated in many tumour cell types 
(Unoki & Nakamura, 2003), and elevated expression of EGR2 is a 
favourable prognostic factor in breast cancer (TCGA, 5- year survival 
for high expressers = 84%; 5- year survival for low expressers = 73%; 
p = 0.000073). Despite this, little attention has been paid to its role 
in senescence. In the present report, our findings indicate a func-
tional role of EGR2 in transcriptional activation of p16 and ARF in 
senescence.
Recently,	EGR2	has	been	defined	as	a	‘pioneer’	transcription	fac-
tor, potentially binding to the genome early on in the onset of senes-
cence (Martínez- Zamudio et al., 2020). Importantly, whilst our data 
demonstrate a role for EGR2 in regulation of senescence, transient 
EGR2 reversal in DS cells does not delineate between the activity 
of EGR2 in senescence onset or maintenance. Future studies using 
stable EGR2 knockdown prior to senescence entry should be per-
formed in order to dissect the roles of EGR2 in the onset and/or 
maintenance of senescence.
4  |  CONCLUDING REMARKS
Our work adds to the growing list of pathways known to directly 
regulate senescence. This includes p16 transcriptional repressors, 
such as homeobox protein HLX1 (Martin et al., 2013) and the N- 
terminal fragment of the GLI2 transcription factor (Bishop et al., 
2010), as well as p16 transcriptional activators such as ETS1 (Ohtani 
et al., 2001) and homeodomain protein MEOX2 (Irelan et al., 2009). 
Importantly, we have demonstrated that EGR2 functions as a direct 
activator of p16/pRB and the ARF/p53/p21 pathways, thus control-
ling both axes of the senescence programme.
It is well established that expression of p16 increases with 
age in human tissues (Krishnamurthy et al., 2006), senescent cells 
accumulate in sites of age- related diseases (Naylor et al., 2012), 
and selective clearance of p16- positive senescent cells in mice has 
been shown to improve health and life span (Baker et al., 2011; 
2016). As such, regulation of the p16/pRB and ARF/p53/p21 path-
ways by EGR2 in senescence may play an important role in ageing 
and age- related diseases.
Furthermore, ten of these genes were identified as hits for se-
nescence reversal in the DS HMEC screen, including p16, and nine of 
these were also identified as hits in the HMF siRNA screen, including 
the top hit S100A4, suggesting that EGR2 may act as a senescence 
regulator by activating the expression of these genes.
Interestingly, EGR2 as a transcription factor has the potential to 
regulate a network of genes in senescence, and nine hits which re-
versed DS HMECs and HMFs were identified to possess an EGR2 
binding site, thus we hypothesise that EGR2 may potentially regulate 
the expression of these genes in senescence, although this has yet 
to be investigated further. Future exploration of the transcriptome 
regulated by EGR2 in senescence could provide new insights into 
regulation of the senescence programme and potentially identify es-
sential senescence mediators, which could be exploited to eliminate 
senescent cells. As implications for senescence have been described 
in vivo for organismal ageing and age- related diseases, furthering 
our understanding of this network in senescence could enable iden-
tification of therapeutic targets for treatment of ageing and age- 
related diseases.
5  |  E XPERIMENTAL PROCEDURES
5.1  |  Cells and reagents
Normal finite life span HMECs and HMFs were obtained from re-
duction mammoplasty tissues of a 21- year- old individual, specimen 
184 and 16- year- old individual, specimen 48, respectively, and were 
cultured as previously described (Garbe et al., 2009). Independent 
HMEC cultures were serially passaged from passage 6 (P6; early pro-
liferating, EP) until p16- dependent, p21- independent stasis. Deeply 
senescent cultures underwent no further expansion upon at least 
two further weeks in culture (DS HMECs; Romanov et al., 2001; 
Garbe et al., 2009; Lowe et al., 2015), and independent HMF cul-
tures were serially passaged from P4 until the population reached 
senescence at P29. DS HMFs underwent no further expansion upon 
at least three further weeks in culture (P29 + 3). Cells were cultured 
at 37°C in the presence of 5% CO2 and atmospheric O2. All cells 
were routinely tested for mycoplasma and shown to be negative.
IMR90 ER:STOP (vector) or ER:RAS (OIS) IMR90 foetal lung fibro-
blasts were produced as described in (Hari et al., 2019) and were a 
kind gift provided by Juan Carlos Acosta. These were maintained in 
DMEM supplemented with 10% FBS and 2 mM l- glutamine.
U2OS cells, primary human fibroblast strain Hs68, and Kit225 
T- lymphocyte cell line were maintained as previously described 
(Gutierrez del Arroyo, 2007). Leiden and Q cells were maintained as 
previously described (Irelan et al., 2009).
5.2  |  siRNA transfections
The fluorescently labelled siRNA targeting cyclophilin B (siGLO) was 
selected as this did not influence the phenotype of either EP or DS 
cultures (Figure S12). HMECs were transfected with 60 nM siGLO 
siRNA (Dharmacon) or p16 siRNA (Qiagen) in 384- well plates using 
Dharmafect 3 (Dharmacon). HMFs were transfected with 30 nM 
siGLO siRNA or p16 siRNA or p21 siRNA (Dharmacon) in 384- well 
plates or 6- well plates using Dharmafect 2 (Dharmacon). DS + siGLO, 
DS + p16 siRNA, DS + p21 siRNA or DS + p16 + p21 siRNA cells were 
harvested for RTqPCR, Western blotting or immunofluorescence as 
detailed below.
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5.3  |  Immunofluorescence
Standard fixation with 3.7% paraformaldehyde, followed by 0.1% 
Triton X permeabilisation and blocking with 0.25% BSA was per-
formed prior to antibody incubations. Primary antibodies used were 
mouseαp16 JC8 (1:200), mouseα8- oxoguanine (1:100, MAB3560 
Millipore), rabbitαp21 (1:1,000, 12D1 Cell Signalling), rabbitαEGR2 
(1:250, H220 Santa Cruz), goatαIL- 6 (1:100, AB- 206- NA R&D 
Systems), followed by donkeyαmouse AlexaFluor- 488 or goatαrabbit 
AlexaFluor- 546 (1:500, Invitrogen), DAPI and Cell Mask Deep 
Red	 (1:10,000,	 Invitrogen).	 For	 5-	bromo-	2′-	deoxyuridine	 (BrdU)	
assays, cells were cultured in 5 µM for 16 h prior to fixation. An 
additional DNA denaturation step with 4 M HCl for 10 min was per-
formed following permeabilisation, and a conjugated mouseαBrdU- 
AlexaFluor- 488 antibody (1:100, B35130 Invitrogen) used. Images 
were collected at 10X using the IN Cell 1000 microscope (GE) and 
the Developer analysis software (GE) was used for image analysis as 
described previously (Bishop et al., 2010).
Please also see Appendix S1.
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